Patents Assigned to The Indiana University Foundation
  • Patent number: 7083979
    Abstract: A method to increase the efficiency of transduction of hematopoietic and other cells by retroviruses includes infecting the cells in the presence of fibronectin or fibronectin fragments. The fibronectin and fibronectin fragments significantly enhance retroviral-mediated gene transfer into the cells, particularly hematopoietic cells including committed progenitors and primitive hematopoietic stem cells. The invention also provides improved methods for somatic gene therapy capitalizing on enhanced gene transfer, hematopoietic cellular populations, and novel constructs for enhancing retroviral-mediated DNA transfer into cells and their use.
    Type: Grant
    Filed: September 13, 1999
    Date of Patent: August 1, 2006
    Assignee: Indiana University Foundation
    Inventors: David A Williams, Vikram P Patel
  • Publication number: 20020168719
    Abstract: The human receptor H4-1BB has been isolated, sequenced and disclosed herein. The cDNA of the human receptor H4-1BB is about 65% homologous to the mouse cDNA 4-1BB and was isolated by using probes derived from cDNA 4-1BB. A fusion protein for detecting cell membrane ligands to human receptor protein H4-1BB was developed. It comprises the extracellular portion of the receptor protein H4-1BB and a detection protein (alkaline phosphatase) bound to the portion of the receptor protein H4-1BB. B-cells that have expressed a ligand to receptor protein H4-1BB can be treated with cells that have expressed receptor protein H4-1BB and B-cell proliferation may be induced. The use of H4-1BB to block H4-1BB ligand binding has practical application in the suppression of the immune system during organ transplantation. A monoclonal antibody against H4-1BB can be used to enhance T-cell proliferation by treating T-cells that have expressed receptor protein H4-1BB with the anti H4-1BB monoclonal antibody.
    Type: Application
    Filed: December 20, 2001
    Publication date: November 14, 2002
    Applicant: Indiana University Foundation
    Inventor: Byoung S. Kwon
  • Patent number: 6455499
    Abstract: Methods of treating a subject having a disorder associated with LHRH activity are disclosed.
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: September 24, 2002
    Assignee: Indiana University Foundation
    Inventor: Roger W. Roeske
  • Patent number: 6399300
    Abstract: Described are preferred myocardial grafts of skeletal myoblasts or cardiomyocytes, and cellular compositions and methods useful in obtaining the grafts. The myocardial grafts are stable and can be used, for example, to deliver recombinant proteins directly to the heart.
    Type: Grant
    Filed: November 16, 1999
    Date of Patent: June 4, 2002
    Assignee: Indiana University Foundation
    Inventor: Loren J. Field
  • Patent number: 6241984
    Abstract: A process for supporting hematopoietic progenitor cells in a culture medium which contains at least one cytokine effective for supporting the cells and preferably, is essentially free of stromal cells.
    Type: Grant
    Filed: March 31, 1994
    Date of Patent: June 5, 2001
    Assignee: The Indiana University Foundation
    Inventors: Ronald Hoffman, John Brandt
  • Patent number: 6165459
    Abstract: Described are preferred processes and compositions for suppressing myeloid cells in mammals. Preferred processes and compositions involve the use of chemokines in synergistic combinations or while they are substantially completely in monomeric form (i.e. substantially free from their polymerized or aggregated forms).
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 26, 2000
    Assignee: Indiana University Foundation
    Inventors: Hal E. Broxmeyer, Scott Cooper, Charles Mantel, Li Lu
  • Patent number: 6159934
    Abstract: Described are novel uses of GHRH-RP polypeptides for specifically activating Sertoli cell expression of stem cell factor and promoting spermatogenesis and fertility, and for inhibiting GHRH-RP activity to decrease or eliminate spermatogenesis and fertility. Also described are pharmaceutical compositions for such uses, and transgenic animals lacking expression of or expressing introduced DNA encoding GHRH-RP polypeptides.
    Type: Grant
    Filed: December 20, 1996
    Date of Patent: December 12, 2000
    Assignee: Indiana University Foundation
    Inventor: Ora H. Pescovitz
  • Patent number: 6143289
    Abstract: Described are preferred processes for suppressing proliferation of or for myeloprotecting myeloid cells in mammals. The processes involve the use of chemokines of the group Macrophage Inflammatory Protein-2.alpha. (MIP-2.alpha.), Platelet Factor 4 (PF4), Interleukin-8 (IL-8) and Macrophage Chemotactic and Activating Factor (MCAF), or involve the use of these chemokines or Macrophage Inflammatory Protein-1.alpha. (MIP-1.alpha.) in synergistic combinations or while they are substantially completely in monomeric form (i.e. substantially free from their polymerized or aggregated forms).
    Type: Grant
    Filed: December 9, 1992
    Date of Patent: November 7, 2000
    Assignee: Indiana University Foundation
    Inventors: Hal E. Broxmeyer, Scott Cooper, Charles Mantel, Li Lu
  • Patent number: 6064180
    Abstract: A neural network characterized by a minimal architecture suitable for implementation in conventional microprocessor battery pack monitoring hardware includes linear and non-linear processing elements and battery parameter measurements representative of real time and temporal quantities whereby state of charge estimations actually converge with 100% and 0% states-of-charge.
    Type: Grant
    Filed: October 29, 1996
    Date of Patent: May 16, 2000
    Assignees: General Motors Corporation, Indiana University Foundation
    Inventors: Michael Scott Sullivan, Ronald David Brost, Yaobin Chen, Russell Carley Eberhart
  • Patent number: 6033907
    Abstract: A method to increase the efficiency of transduction of hematopoietic and other cells by retroviruses includes infecting the cells in the presence of fibronectin or fibronectin fragments. The fibronectin and fibronectin fragments significantly enhance retroviral-mediated gene transfer into the cells, particularly hematopoietic cells including committed progenitors and primitive hematopoietic stem cells. The invention also provides improved methods for somatic gene therapy capitalizing on enhanced gene transfer, hematopoietic cellular populations, and novel constructs for enhancing retroviral-mediated DNA transfer into cells and their use.
    Type: Grant
    Filed: September 29, 1995
    Date of Patent: March 7, 2000
    Assignee: Indiana University Foundation
    Inventor: David A. Williams
  • Patent number: 6015671
    Abstract: Described are preferred myocardial grafts of skeletal myoblasts or cardiomyocytes, and cellular compositions and methods useful in obtaining the grafts. The myocardial grafts are stable and can be used, for example, to deliver recombinant proteins directly to the heart.
    Type: Grant
    Filed: November 21, 1997
    Date of Patent: January 18, 2000
    Assignee: Indiana University Foundation
    Inventor: Loren J. Field
  • Patent number: 5972380
    Abstract: Described are reversibly N-acylated phosphotidylserine and phosphatidylethanolamine derivatives which are useful as caged aminophospholipids. Also described are pharmaceutical preparations containing pH-sensitive liposomes formed with the caged aminophospholipids, and related methods.
    Type: Grant
    Filed: June 16, 1998
    Date of Patent: October 26, 1999
    Assignee: Indiana University Foundation
    Inventor: David L. Daleke
  • Patent number: 5932432
    Abstract: Described is a novel in vitro method for obtaining and identifying proteins which, in their natural in vivo setting, are covalently modified after translation. To identify novel isoprenylated proteins for subsequent biochemical study, colony blots of a Glycine max cDNA expression library were ?.sup.3 H! farnesyl labeled in vitro. Proteins identified by this screen contained several different carboxy-termini that conform to consensus farnesylation motifs. These proteins included known farnesylated proteins (DnaJ homologs) and several novel proteins, two of which contained 6 or more tandem repeats of a hexapeptide having the consensus sequence ?E or G! ?G or P!EK?P or K!K. Expression library screening by direct labeling can thus be adapted to recover and identify isoprenylated proteins as well as proteins with other post-translational modifications.
    Type: Grant
    Filed: January 21, 1997
    Date of Patent: August 3, 1999
    Assignee: Indiana University Foundation
    Inventors: Dring N. Crowell, Brenda Biermann, Stephen Randall
  • Patent number: 5879883
    Abstract: Method for screening for risk of Alzheimer's disease involve assaying for a guanine to thymine substitution at position 1924 of the gene encoding the human amyloid precursor protein. Also described are transgenic mammals harboring an expressable gene sequence encoding human amyloid precursor protein having a phenyanine for valine amino acid substitution in the transmembrane domain of the amyloid precursor protein.
    Type: Grant
    Filed: May 3, 1995
    Date of Patent: March 9, 1999
    Assignee: Indiana University Foundation
    Inventors: Merrill D. Benson, Jill Murrell, Martin Farlow, Bernardino Ghetti
  • Patent number: 5849869
    Abstract: The present invention relates to nucleotide sequences of the Delta genes, and amino acid sequence of the encoded protein, fragments and derivatives which retain binding activity are also provided.
    Type: Grant
    Filed: November 28, 1994
    Date of Patent: December 15, 1998
    Assignees: Yale University, Indiana University Foundation
    Inventors: Spyridon Artavanis-Tsakonas, Marc Alan-Telander Muskavitch, Richard Grant Fehon, Scott Brockwell Shephard
  • Patent number: 5840059
    Abstract: A system for treating a patient's heart which comprises a means to form channels in the heart wall and a means to deliver a therapeutic or diagnostic agent into the channels. Additionally, the system may comprise a way to retain the agent within the channels for a useful period of time. The system may be configured to be introduced percutaneously or intraoperatively. The system generally comprises an elongated, flexible lasing transmission catheter that emits laser radiation and has delivery lumen opening at the distal end. Practice of the invention comprises forming channels in the heart wall and delivering a therapeutic or diagnostic agent into the channel. Gene therapy agents of this invention comprise vectors for transferring genetic information to the heart tissue in vivo or harvested cells which have been genetically engineered in vitro. Additionally, the invention may comprise retaining the agent within the channels, for example, by incorporating the agent in a viscous carrier.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 24, 1998
    Assignees: CardioGenesis Corporation, Indiana University Foundation, Columbia University
    Inventors: Keith L. March, Michael Aita, Randy Kesten, Craig Smith
  • Patent number: 5810850
    Abstract: The invention provides a device having two components: a needle advancing apparatus slidable longitudinally along a catheter to advance needles into a tissue membrane, such as a blood vessel wall, around an opening in the membrane; and, a suture retrieval assembly insertable through the catheter beyond a distal side of the tissue membrane. The needle advancing apparatus advances suture through the tissue wall. The suture retrieval assembly grabs the suture on the distal side of the tissue membrane for extraction thereof through the opening in the tissue membrane. A method for suturing a membrane beneath the patient's skin is also disclosed.
    Type: Grant
    Filed: September 23, 1997
    Date of Patent: September 22, 1998
    Assignee: Indiana University Foundation
    Inventors: David Hathaway, Brian Patton, Keith L. March
  • Patent number: 5797870
    Abstract: A method for treating a patient's heart which comprising delivering a gene therapy agent into the pericardial sac around the patient's heart. The agent is introduced surgically or by transvascular means such as a catheter which has been introduced percutaneously or otherwise. Introducing the gene therapy agent into the pericardial sac contains the agent, allowing high concentration of the agent adjacent large regions of the epicardium and pericardium without spillage or systemic distribution to other organs or tissues. The gene therapy agents of this invention comprise vectors for transferring genetic information to the epicardial cells in vivo or harvested cells which have been genetically engineered in vitro. In a preferred embodiment, a catheter is percutaneously introduced, such as through the femoral artery, and guided upstream into the left ventricle. The distal end of the catheter advanced until it penetrates through the epicardium so that agent can be introduced into the pericardial space.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 25, 1998
    Assignee: Indiana University Foundation
    Inventors: Keith L. March, Douglas P. Zipes
  • Patent number: 5779949
    Abstract: A process is provided for converting lead-contaminated soil to commercially-useful ceramic shapes, in which the lead is covalently-bonded and from which it does not leach. The soil is mixed with conventional brick or tile fabricating ingredients to form a premix which is formed into a suitable shape and fired at a temperature in the range of 150.degree. F. to 250.degree. F.
    Type: Grant
    Filed: August 14, 1996
    Date of Patent: July 14, 1998
    Assignee: Indiana University Foundation
    Inventors: Glenn M. Mason, Edward M. Bryan
  • Patent number: 5770966
    Abstract: A one-diode circuit for negated implication (.about..fwdarw.) is derived from a 12-transistor Lukasiewicz implication circuit (.fwdarw.). The derivation also yields an adjustable three-transistor implication circuit with maximum error less than 1% of full scale. Two Lukasiewicz logic arrays (.English Pound.LAs) are proposed that use area-efficient implementations of the one-diode and three-transistor implication circuits. The very dense diode-tower .English Pound.LA contains 36,000 implications in an area that previously held 92 implications; the three-transistor .English Pound.LA contains 1,990 implications. Both .English Pound.LAs double the number of inputs per pin on the IC package. Very dense .English Pound.LAs make .English Pound.LA-based fuzzy controllers and neural networks practical. As an example, an .English Pound.LA retina that detects edges in 15 nanoseconds is described.
    Type: Grant
    Filed: January 15, 1997
    Date of Patent: June 23, 1998
    Assignee: Indiana University Foundation
    Inventor: Jonathan W. Mills